• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Nagilactone E 通过激活肺癌细胞中的 c-Jun 增加 PD-L1 的表达。

Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells.

机构信息

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China; School of Medicine, Chengdu University, Chengdu 610106, China.

出版信息

Chin J Nat Med. 2020 Jul;18(7):517-525. doi: 10.1016/S1875-5364(20)30062-5.

DOI:10.1016/S1875-5364(20)30062-5
PMID:32616192
Abstract

Nagilactone E (NLE), a natural product with anticancer activities, is isolated from Podocarpus nagi. In this study, we reported that NLE increased programmed death ligand 1 (PD-L1) expressions at both protein and mRNA levels in human lung cancer cells, and enhanced its localization on the cell membrane. Mechanistically, NLE increased the phosphorylation and expression of c-Jun, and promoted the localization of c-Jun in the nucleus, while silencing of c-Jun by small interfering RNA (siRNA) reduced NLE-induced PD-L1. Further study showed that NLE activated the c-Jun N-terminal kinases (JNK), the upstream of c-Jun, and its inhibitor SP600125 reversed the NLE-increased PD-L1. Moreover, NLE-induced PD-L1 increased the binding intensity of PD-1 on the cell surface. In summary, NLE upregulates the expression of PD-L1 in lung cancer cells through the activation of JNK-c-Jun axis, which has the potential to combine with the PD-1/PD-L1 antibody therapies in lung cancer.

摘要

那格列酮 E(NLE)是一种具有抗癌活性的天然产物,从罗汉松中分离得到。在这项研究中,我们报道 NLE 可在蛋白和 mRNA 水平上增加人肺癌细胞中程序性死亡配体 1(PD-L1)的表达,并增强其在细胞膜上的定位。在机制上,NLE 增加了 c-Jun 的磷酸化和表达,并促进 c-Jun 定位于细胞核,而通过小干扰 RNA(siRNA)沉默 c-Jun 可减少 NLE 诱导的 PD-L1。进一步的研究表明,NLE 激活了 c-Jun N 端激酶(JNK),即 c-Jun 的上游激酶,其抑制剂 SP600125 逆转了 NLE 增加的 PD-L1。此外,NLE 诱导的 PD-L1 增加了 PD-1 在细胞表面的结合强度。总之,NLE 通过激活 JNK-c-Jun 轴上调肺癌细胞中 PD-L1 的表达,这有可能与肺癌中的 PD-1/PD-L1 抗体疗法相结合。

相似文献

1
Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells.Nagilactone E 通过激活肺癌细胞中的 c-Jun 增加 PD-L1 的表达。
Chin J Nat Med. 2020 Jul;18(7):517-525. doi: 10.1016/S1875-5364(20)30062-5.
2
Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer.谷氨酰胺耗竭通过激活 EGFR/ERK/c-Jun 信号通路诱导肾癌中 PD-L1 的表达。
Mol Cancer Res. 2020 Feb;18(2):324-339. doi: 10.1158/1541-7786.MCR-19-0517. Epub 2019 Oct 31.
3
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.通过 COP1/c-Jun/HDAC3 轴增强 PD-L1 启动子上的组蛋白 H3 乙酰化对于耐药癌细胞中 PD-L1 的表达是必需的。
J Exp Clin Cancer Res. 2020 Feb 5;39(1):29. doi: 10.1186/s13046-020-1536-x.
4
Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells.下调细胞周期蛋白 B1 介导纳吉利酮 E 诱导非小细胞肺癌细胞 G2 期细胞周期阻滞。
Eur J Pharmacol. 2018 Jul 5;830:17-25. doi: 10.1016/j.ejphar.2018.04.020. Epub 2018 Apr 19.
5
Identification of nagilactone E as a protein synthesis inhibitor with anticancer activity.鉴定那格列酮 E 是一种具有抗癌活性的蛋白质合成抑制剂。
Acta Pharmacol Sin. 2020 May;41(5):698-705. doi: 10.1038/s41401-019-0332-7. Epub 2020 Feb 11.
6
Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer.不可逆的 JNK 阻断克服了结直肠癌中 PD-L1 介导的化疗耐药性。
Oncogene. 2021 Aug;40(32):5105-5115. doi: 10.1038/s41388-021-01910-6. Epub 2021 Jun 30.
7
Induction of PD-L1 by Nitric Oxide via JNK Activation in A172 Glioblastoma Cells.一氧化氮通过 JNK 激活诱导 A172 神经胶质瘤细胞程序性死亡配体 1 的表达。
Biol Pharm Bull. 2020 Jun 1;43(6):1020-1022. doi: 10.1248/bpb.b20-00087. Epub 2020 Mar 20.
8
BRAF-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts.BRAF 诱导的肿瘤内在 PD-L1 可调节人结肠癌细胞和肿瘤异种移植物中的化疗诱导的细胞凋亡。
Oncogene. 2019 Oct;38(41):6752-6766. doi: 10.1038/s41388-019-0919-y. Epub 2019 Aug 12.
9
Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis.抗癌药物诱导凋亡过程中c-Jun氨基末端激酶途径介导的乙酰胆碱酯酶表达
Oncogene. 2006 Nov 9;25(53):7070-7. doi: 10.1038/sj.onc.1209686. Epub 2006 May 22.
10
Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.甘草查尔酮 A 抑制肺癌细胞中干扰素-γ诱导的程序性死亡配体 1。
Phytomedicine. 2021 Jan;80:153394. doi: 10.1016/j.phymed.2020.153394. Epub 2020 Oct 22.

引用本文的文献

1
From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer.从免疫检查点到治疗方法:了解免疫检查点调控以及天然产物和传统医学对肺癌免疫检查点和免疫治疗的影响。
Front Immunol. 2024 Feb 15;15:1340307. doi: 10.3389/fimmu.2024.1340307. eCollection 2024.
2
DDR1 functions as an immune negative factor in colorectal cancer by regulating tumor-infiltrating T cells through IL-18.DDR1 通过调节肿瘤浸润 T 细胞来发挥免疫负因子的作用,从而调控结直肠癌中的 IL-18。
Cancer Sci. 2022 Nov;113(11):3672-3685. doi: 10.1111/cas.15533. Epub 2022 Aug 24.
3
Dexmedetomidine Attenuates LPS-Stimulated Alveolar Type II Cells' Injury through Upregulation of miR-140-3p and Partial Suppression of PD-L1 Involving Inactivating JNK-Bnip3 Pathway.
右美托咪定通过上调 miR-140-3p 和部分抑制 PD-L1 来抑制 JNK-Bnip3 通路的活化,从而减轻 LPS 刺激的肺泡 II 型细胞损伤。
Can Respir J. 2022 Jul 31;2022:8433960. doi: 10.1155/2022/8433960. eCollection 2022.
4
c-MYC-mediated TRIB3/P62 aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2.c-MYC介导的TRIB3/P62聚集体积累在依维莫司和人参皂苷Rh2联合使用时引发副凋亡。
Acta Pharm Sin B. 2022 Mar;12(3):1240-1253. doi: 10.1016/j.apsb.2021.09.014. Epub 2021 Sep 22.
5
Enhanced tumor homing of pathogen-mimicking liposomes driven by R848 stimulation: A new platform for synergistic oncology therapy.R848刺激驱动的病原体模拟脂质体增强肿瘤归巢:协同肿瘤治疗的新平台
Acta Pharm Sin B. 2022 Feb;12(2):924-938. doi: 10.1016/j.apsb.2021.08.018. Epub 2021 Aug 21.
6
Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets.具有多种生物靶点的合成和天然杂环抗癌化合物。
Molecules. 2021 Nov 25;26(23):7134. doi: 10.3390/molecules26237134.
7
Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer.天然产物单独或与美国食品药品监督管理局(FDA)批准的药物联合使用,用于治疗新冠肺炎和肺癌。
Biomedicines. 2021 Jun 18;9(6):689. doi: 10.3390/biomedicines9060689.
8
Biological Activity of Selected Natural and Synthetic Terpenoid Lactones.部分天然和合成萜类内酯的生物活性
Int J Mol Sci. 2021 May 10;22(9):5036. doi: 10.3390/ijms22095036.
9
Anticancer Activities and Mechanism of Action of Nagilactones, a Group of Terpenoid Lactones Isolated from Podocarpus Species.从罗汉松属植物中分离得到的萜类内酯——纳吉尔内酯的抗癌活性及作用机制
Nat Prod Bioprospect. 2020 Dec;10(6):367-375. doi: 10.1007/s13659-020-00268-8. Epub 2020 Oct 9.